LEQEMBI® IQLIK™ Autoinjector Recognized by TIME as a Top Invention of 2025

LEQEMBI® IQLIK™: A Revolutionary Advancement in Alzheimer’s Care

Eisai Co., Ltd. alongside Biogen Inc. has garnered significant recognition for their groundbreaking product, LEQEMBI® IQLIK™. This innovative subcutaneous autoinjector, designed for the administration of lecanemab to treat Alzheimer's disease (AD), has recently been honored as one of TIME's “Best Inventions of 2025.” This accolade underscores the increasing acknowledgment of advancements in the medical field, particularly those that enhance patient care and treatment experiences.

Overview of LEQEMBI® IQLIK™

LEQEMBI® IQLIK™ is distinguished as the first anti-amyloid treatment allowing patients to self-administer the medication at home. This feature enables continued management of Alzheimer's disease progression after an initial 18-month treatment phase. The device was officially approved by the U.S. Food and Drug Administration (FDA) in August 2025 and launched shortly after, marking a significant milestone in the treatment landscape for Alzheimer's patients.

This innovative treatment not only simplifies the administration process but also greatly reduces the burden on healthcare resources. Patients can now administer the injection themselves in about 15 seconds without undergoing lengthy infusion sessions, thereby eliminating the need to frequently visit infusion centers. This self-administration option promises to increase accessibility for patients and their caregivers, who play a crucial role in managing the disease’s progression.

The Selection Process for TIME's Best Inventions

To select the best inventions each year, TIME editors and correspondents gather nominations from around the world, emphasizing creativity and impact across various sectors, particularly medical technology and artificial intelligence. The 2025 list included 300 innovative solutions that aim to enhance and transform lives, showcasing the increasing overlap between technological advancement and healthcare.

The Importance of LEQEMBI® IQLIK™

The launch of LEQEMBI® marks a pivotal moment in Alzheimer’s treatment. With its unique at-home administration capabilities, it aims to empower patients and their families. By allowing patients to continue their treatment without hindrance or frequent trips to medical facilities, it serves to enhance their quality of life. Moreover, the potential to limit the need for extensive healthcare resources, such as infusion preparations and nursing supervision, is a significant advancement in streamlining Alzheimer’s treatment pathways.

Previously known as one of TIME's “Best Inventions of 2023,” LEQEMBI®, represents a monumental step forward in anti-amyloid therapies. It has been shown to slow cognitive and functional decline in individuals with Mild Cognitive Impairment (MCI) and early stages of dementia, addressing a critical need in Alzheimer’s care.

In addition to its practicality, LEQEMBI® has gained approval across 50 countries and is currently undergoing regulatory review in an additional 10, indicating a global recognition of its potential benefits.

Risks and Safety Information

While LEQEMBI® offers promising benefits, it is crucial to be aware of potential safety concerns. As a monoclonal antibody targeting beta-amyloid aggregates, it can cause “Amyloid-Related Imaging Abnormalities” (ARIA), which may present various symptoms, including but not limited to headache and confusion. The incidence of ARIA requires careful monitoring, particularly in individuals with specific genetic markers like apolipoprotein E ε4 homozygotes, as they face a higher risk.

Eisai emphasizes the importance of patient education, particularly regarding the use of genetic testing to inform treatment decisions and manage risks effectively. Therefore, continuous evaluation and monitoring by healthcare professionals are essential when using LEQEMBI® for treatment.